What is Brief History of 3SBio Company?

What is the history of 3SBio?

3SBio Inc. has established itself as a key player in the biotechnology field, particularly in China, by consistently introducing groundbreaking biopharmaceutical products. A significant milestone was the 1998 introduction of EPIAO, a recombinant human erythropoietin injection, which rapidly became a dominant brand in China's erythropoietin market.

Founded in 1993 by Dr. Jing Lou and Dan Lou, with its headquarters in Shenyang, Liaoning, China, 3SBio's core mission was to enhance patient care through the research, development, manufacturing, and marketing of superior biopharmaceutical products.

The company's journey began with a focus on critical medical needs, setting a precedent in China's developing biotechnology landscape. Today, 3SBio holds a strong market presence, notably with its flagship product TPIAO, the world's sole commercial recombinant human thrombopoietin (rhTPO). This product achieved RMB 5.062 billion in sales in 2024, marking a 20.4% increase from the previous year. The company's evolution from a startup to a leading biopharmaceutical entity, boasting a strong product pipeline and international ambitions, underscores its strategic growth and unwavering dedication to innovation, including advancements in areas like the 3SBio BCG Matrix.

The 3SBio company history began in 1993 with the establishment of Shenyang Sunshine Pharmaceuticals Co., Ltd. in Shenyang, Liaoning, China. Major General Lou Dan, a distinguished bioengineering medical expert, led the founding team, aiming to meet China's growing need for advanced medical treatments, particularly in recombinant protein products. This marked the inception of what would become a significant player in China's biotechnology sector.

3SBio's Founding and Early Milestones

The 3SBio origins trace back to 1993, founded by Major General Lou Dan and his team. The company's early focus was on addressing the increasing demand for advanced therapies in China, with a strategic emphasis on recombinant protein products. This foundational period set the stage for the company's future development and achievements.

• Founded in 1993 by Major General Lou Dan and his team.
• Originally named Shenyang Sunshine Pharmaceuticals Co., Ltd.
• Established in Shenyang, Liaoning, China.
• Focused on recombinant protein products to meet domestic demand.

The 3SBio timeline saw a significant early achievement in April 1995 with the NMPA approval of Intefen (recombinant human interferon α2a injection). This was followed by its inclusion in the National Medical Insurance Catalogue as a Category B drug in December 1995, a crucial step for accessibility. The company's commitment to affordability was highlighted in 2000 when Mr. Lou Dan proposed making Interferon as accessible as penicillin, initiating a price reduction trend within the biopharmaceutical industry. Another key product, Inleusin (recombinant human interleukin-2 for injection), was launched in March 1996, further expanding the company's therapeutic offerings. While specific initial funding details are not widely publicized, the company's consistent growth suggests early strategic financial backing, essential for its Growth Strategy of 3SBio.

Complete 3SBio Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The early years of 3SBio were marked by a strong focus on product development and market penetration, setting the stage for its future expansion. The company successfully launched several key biopharmaceutical products, solidifying its position in the domestic market.

Product Launches and Market Dominance

Following the initial success of Intefen and Inleusin, 3SBio introduced EPIAO in 1998. By 2002, EPIAO had become a leading product in China's erythropoietin market. This product, alongside SEPO, continued to hold a significant market share, accounting for 42.7% in the first half of 2024.

Strategic Acquisitions and Global Reach

3SBio's growth trajectory included strategic international expansion through acquisitions. In 2009, the company acquired Sciprogen Co. and Sirton, marking its initial foray into global markets. Further solidifying its international presence, 3SBio acquired the Canadian biomanufacturing business of Therapure Biopharma Inc. in 2017 for US$290 million.

Partnerships and Financial Growth

In 2010, a significant strategic alliance was formed with Ascentage Pharma Group Corporation, Ltd., involving a US$3 million investment for the research and development of targeted cancer therapeutics. This collaboration granted 3SBio exclusive rights within China. The company's financial performance has been robust, with revenue in 2024 reaching approximately RMB 9.108 billion, a 16.5% year-on-year increase. Net profit attributable to owners of the parent also saw a substantial rise of 34.9% year-on-year, reaching approximately RMB 2.09 billion.

Market Performance and Listing Milestones

3SBio's market leadership is evident in its product performance, with TPIAO holding a 66.2% market share in Mainland China for the treatment of thrombocytopenia based on sales value in the first half of 2024. The company's journey included listing on NASDAQ, subsequent privatization, and a successful listing on HKEX (1530.HK) in 2015. As of July 24, 2025, 3SBio's market capitalization is valued at $9.1 billion, reflecting its significant achievements in the biotechnology sector. This detailed account is part of the Brief History of 3SBio.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The history of 3SBio is marked by significant milestones and groundbreaking innovations in the biopharmaceutical sector, alongside the inherent challenges of a rapidly evolving industry. The company's journey showcases a commitment to advancing healthcare through scientific discovery and strategic growth, contributing to its prominent position in the market.

3SBio's innovation is exemplified by TPIAO, the world's sole commercial recombinant human thrombopoietin (rhTPO), which achieved sales of RMB 5.062 billion in 2024. The company also pioneered Yisaipu, China's first tumor necrosis factor (TNF-α) inhibitor, and Cipterbin, China's first innovative anti-HER2 monoclonal antibody with an engineered Fc region, underscoring its dedication to developing novel therapies.

TPIAO Commercialization

TPIAO, a key product, generated RMB 5.062 billion in sales in 2024. Its approval for pediatric use and inclusion in the NRDL highlight its market impact and accessibility.

Yisaipu and Cipterbin Development

The company's portfolio includes Yisaipu, China's first TNF-α inhibitor, and Cipterbin, an innovative anti-HER2 monoclonal antibody. These products demonstrate 3SBio's capability in developing first-in-class biopharmaceuticals.

Therapeutic Area Expansion

3SBio has broadened its focus to include oncology, nephrology, autoimmune diseases, hair health, and dermatology. This expansion reflects a strategic approach to addressing diverse medical needs.

Global Strategic Partnership

The partnership with Pfizer for SSGJ-707, a bispecific antibody, secured an upfront payment of $1.25 billion and a $100 million equity investment. This collaboration signifies global recognition of 3SBio's R&D prowess.

Pipeline Advancement

In 2024, three drugs were approved for commercial launch, and new drug applications were submitted for four products, including long-acting erythropoietin (SSS06). As of March 2025, 3SBio has 30 product candidates in its pipeline, with 10 in clinical phase III.

Quality and Compliance

The company's production lines have received the latest Good Manufacturing Practice (GMP) certification from the National Medical Products Administration. This adherence to stringent quality standards is crucial for drug manufacturing.

The biotechnology industry presents inherent challenges, including the constant need for innovation and navigating complex regulatory environments. 3SBio addresses these by integrating in-house R&D with strategic external collaborations to expedite drug development. Understanding the Target Market of 3SBio is also key to overcoming market access hurdles.

Continuous Innovation Imperative

The competitive landscape demands ongoing investment in research and development to bring novel therapies to market. Staying ahead requires a proactive approach to scientific discovery and technological advancement.

Navigating Regulatory Frameworks

Successfully bringing new drugs to patients involves meticulous adherence to evolving regulatory requirements. This necessitates robust data generation and clear communication with health authorities.

Balancing In-house and External R&D

While internal research drives core innovation, strategic partnerships are vital for accelerating development timelines and expanding therapeutic reach. This dual approach is critical for sustained growth.

Pipeline Management and Execution

Managing a diverse pipeline of 30 product candidates, with 10 in late-stage clinical trials, requires significant operational expertise. Efficient execution is paramount to translating research into commercial success.

Market Access and Reimbursement

Securing market access and favorable reimbursement status, as seen with TPIAO's NRDL renewal, is crucial for product uptake. This involves demonstrating clinical value and economic benefits to payers.

Global Competition

Operating in a global biopharmaceutical market means competing with established international players. Maintaining a competitive edge requires continuous investment in cutting-edge science and efficient operations.

3SBio Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

The journey of 3SBio, a prominent biotechnology company, began in 1993 with its establishment in Shenyang, China. Over the years, the company has achieved significant milestones, expanding its product portfolio and global reach. This brief history of 3SBio highlights its evolution from its inception to its current standing in the biotechnology sector.

Strategic Focus Areas

3SBio is concentrating its efforts on key therapeutic areas including hematology, oncology, nephrology, autoimmune diseases, hair health, and dermatology. This strategic focus aims to drive innovation and address significant unmet medical needs.

R&D and Partnerships

The company plans to bolster its competitive edge by strengthening its innovation pipeline through a combination of in-house research and development and strategic external collaborations. This dual approach accelerates the development of novel therapies.

Financial Projections

Analysts project that 3SBio's revenue and net profit will experience compound annual growth rates of 13.5% and 16%, respectively, between 2024 and 2034. Organic product revenue growth for 2025 is anticipated to be in the double digits.

Global Vision

Adopting a global perspective, 3SBio is committed to advancing the development of innovative drugs worldwide. This outlook aligns with its founding vision of enhancing patient outcomes through high-quality, groundbreaking therapies, as further detailed in the Competitors Landscape of 3SBio.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE